Haleon plc (LON:HLN)

Market Cap	33.77B -5.7%
Revenue (ttm)	11.03B -1.8%
Net Income	1.67B +15.6%
EPS	0.19 +17.8%
Shares Out	8.91B
PE Ratio	20.50
Forward PE	18.42
Dividend	0.07 (1.84%)
Ex-Dividend Date	Apr 9, 2026

Volume	13,023,620
Average Volume	24,783,990
Open	381.60
Previous Close	386.20
Day's Range	377.90 - 385.80
52-Week Range	274.40 - 419.50
Beta	0.25
RSI	45.87
Earnings Date	Feb 25, 2026

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal dr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1715
• Employees: 24,535
• Stock Exchange: London Stock Exchange
• Ticker Symbol: HLN

Financial Performance

In 2025, Haleon's revenue was 11.03 billion, a decrease of -1.81% compared to the previous year's 11.23 billion. Earnings were 1.67 billion, an increase of 15.60%.